Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G)
CONCLUSION: Our data show the potential efficacy and acceptable safety profile of FTD/TPI plus bevacizumab for vulnerable patients with pretreated mCRC.PMID:37950903 | DOI:10.1093/oncolo/oyad296 (Source: The Oncologist)
Source: The Oncologist - November 11, 2023 Category: Cancer & Oncology Authors: Yosuke Kito Hisato Kawakami Seiichiro Mitani Shinichi Nishina Toshihiko Matsumoto Takao Tsuzuki Yudai Shinohara Hozumi Shimokawa Ryosuke Kumanishi Takashi Ohta Hiroo Katsuya Takeshi Kawakami Tomohiro Nishina Hiroko Hasegawa Kohei Akiyoshi Yasutaka Chiba K Source Type: research
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma
CONCLUSION: A small subset of patients lacking a response to nivolumab derive benefit from salvage nivolumab plus ipilimumab. When possible, both drugs should be given in concomitantly, rather in an adaptive fashion.PMID:37950901 | DOI:10.1093/oncolo/oyad298 (Source: The Oncologist)
Source: The Oncologist - November 11, 2023 Category: Cancer & Oncology Authors: Rana R McKay Katharina Leucht Wanling Xie Opeyemi Jegede David A Braun Michael B Atkins Marc-Oliver Grimm Toni K Choueiri Source Type: research
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G)
CONCLUSION: Our data show the potential efficacy and acceptable safety profile of FTD/TPI plus bevacizumab for vulnerable patients with pretreated mCRC.PMID:37950903 | DOI:10.1093/oncolo/oyad296 (Source: The Oncologist)
Source: The Oncologist - November 11, 2023 Category: Cancer & Oncology Authors: Yosuke Kito Hisato Kawakami Seiichiro Mitani Shinichi Nishina Toshihiko Matsumoto Takao Tsuzuki Yudai Shinohara Hozumi Shimokawa Ryosuke Kumanishi Takashi Ohta Hiroo Katsuya Takeshi Kawakami Tomohiro Nishina Hiroko Hasegawa Kohei Akiyoshi Yasutaka Chiba K Source Type: research
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma
CONCLUSION: A small subset of patients lacking a response to nivolumab derive benefit from salvage nivolumab plus ipilimumab. When possible, both drugs should be given in concomitantly, rather in an adaptive fashion.PMID:37950901 | DOI:10.1093/oncolo/oyad298 (Source: The Oncologist)
Source: The Oncologist - November 11, 2023 Category: Cancer & Oncology Authors: Rana R McKay Katharina Leucht Wanling Xie Opeyemi Jegede David A Braun Michael B Atkins Marc-Oliver Grimm Toni K Choueiri Source Type: research
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G)
CONCLUSION: Our data show the potential efficacy and acceptable safety profile of FTD/TPI plus bevacizumab for vulnerable patients with pretreated mCRC.PMID:37950903 | DOI:10.1093/oncolo/oyad296 (Source: The Oncologist)
Source: The Oncologist - November 11, 2023 Category: Cancer & Oncology Authors: Yosuke Kito Hisato Kawakami Seiichiro Mitani Shinichi Nishina Toshihiko Matsumoto Takao Tsuzuki Yudai Shinohara Hozumi Shimokawa Ryosuke Kumanishi Takashi Ohta Hiroo Katsuya Takeshi Kawakami Tomohiro Nishina Hiroko Hasegawa Kohei Akiyoshi Yasutaka Chiba K Source Type: research
Opioid and Non-Opioid Pharmacotherapy Use for Pain Management Among Privately Insured Pediatric Patients With Cancer in the United States
CONCLUSION: There has been a downward trend in the use of opioids in recent years among pediatric patients with cancer and an upward trend in the use of non-opioid pharmacotherapy for pain management potentially as an alternative to opioids.PMID:37944042 | DOI:10.1093/oncolo/oyad292 (Source: The Oncologist)
Source: The Oncologist - November 9, 2023 Category: Cancer & Oncology Authors: Chan Shen J Douglas Thornton Ning Li Eric Schaefer Shouhao Zhou Sarah Kawasaki Colette Pameijer Douglas Leslie Source Type: research
Opioid and Non-Opioid Pharmacotherapy Use for Pain Management Among Privately Insured Pediatric Patients With Cancer in the United States
CONCLUSION: There has been a downward trend in the use of opioids in recent years among pediatric patients with cancer and an upward trend in the use of non-opioid pharmacotherapy for pain management potentially as an alternative to opioids.PMID:37944042 | DOI:10.1093/oncolo/oyad292 (Source: The Oncologist)
Source: The Oncologist - November 9, 2023 Category: Cancer & Oncology Authors: Chan Shen J Douglas Thornton Ning Li Eric Schaefer Shouhao Zhou Sarah Kawasaki Colette Pameijer Douglas Leslie Source Type: research
Opioid and Non-Opioid Pharmacotherapy Use for Pain Management Among Privately Insured Pediatric Patients With Cancer in the United States
CONCLUSION: There has been a downward trend in the use of opioids in recent years among pediatric patients with cancer and an upward trend in the use of non-opioid pharmacotherapy for pain management potentially as an alternative to opioids.PMID:37944042 | DOI:10.1093/oncolo/oyad292 (Source: The Oncologist)
Source: The Oncologist - November 9, 2023 Category: Cancer & Oncology Authors: Chan Shen J Douglas Thornton Ning Li Eric Schaefer Shouhao Zhou Sarah Kawasaki Colette Pameijer Douglas Leslie Source Type: research
Coping and Perception of Prognosis in Patients With Indolent Non-Hodgkin's Lymphoma
DISCUSSION: Patients with iNHL report substantial psychological distress, a diversity of coping strategies, and complex cognitive understanding of their prognosis. Interventions, which address prognostic uncertainty and promote positive emotional coping with prognosis, may ameliorate psychological distress in this population.PMID:37935593 | DOI:10.1093/oncolo/oyad295 (Source: The Oncologist)
Source: The Oncologist - November 7, 2023 Category: Cancer & Oncology Authors: Richard A Newcomb P Connor Johnson Daniel Yang Katherine Holmbeck Joanna Choe Anisa Nabily Porsha Lark Tejaswini Dhawale Hermioni L Amonoo Areej El-Jawahri Source Type: research
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial
CONCLUSION: This study is the first analysis of CTCs modeling for stage IV disease stratification. These results show the need to expand biomarker profiling in combination with CTCs stratification for improved biomarker-driven drug development.PMID:37935631 | DOI:10.1093/oncolo/oyad293 (Source: The Oncologist)
Source: The Oncologist - November 7, 2023 Category: Cancer & Oncology Authors: Lorenzo Gerratana Masha Kocherginsky Andrew A Davis Paolo D'Amico Carolina Reduzzi Fabio Puglisi Massimo Cristofanilli Source Type: research
Coping and Perception of Prognosis in Patients With Indolent Non-Hodgkin's Lymphoma
DISCUSSION: Patients with iNHL report substantial psychological distress, a diversity of coping strategies, and complex cognitive understanding of their prognosis. Interventions, which address prognostic uncertainty and promote positive emotional coping with prognosis, may ameliorate psychological distress in this population.PMID:37935593 | DOI:10.1093/oncolo/oyad295 (Source: The Oncologist)
Source: The Oncologist - November 7, 2023 Category: Cancer & Oncology Authors: Richard A Newcomb P Connor Johnson Daniel Yang Katherine Holmbeck Joanna Choe Anisa Nabily Porsha Lark Tejaswini Dhawale Hermioni L Amonoo Areej El-Jawahri Source Type: research
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial
CONCLUSION: This study is the first analysis of CTCs modeling for stage IV disease stratification. These results show the need to expand biomarker profiling in combination with CTCs stratification for improved biomarker-driven drug development.PMID:37935631 | DOI:10.1093/oncolo/oyad293 (Source: The Oncologist)
Source: The Oncologist - November 7, 2023 Category: Cancer & Oncology Authors: Lorenzo Gerratana Masha Kocherginsky Andrew A Davis Paolo D'Amico Carolina Reduzzi Fabio Puglisi Massimo Cristofanilli Source Type: research
Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda
CONCLUSION: Despite health insurance which covers many elements of cancer care, a substantial proportion of patients on anti-cancer treatment in Rwanda experience major financial toxicity. Novel health financing solutions are needed to ensure accessible and affordable cancer care.PMID:37897406 | DOI:10.1093/oncolo/oyad291 (Source: The Oncologist)
Source: The Oncologist - October 28, 2023 Category: Cancer & Oncology Authors: Fidel Rubagumya Brooke Wilson Achille Manirakiza Emmanuel Mutabazi Diane A Ndoli Emmanuel Rudakemwa Mary D Chamberlin Wilma M Hopman Christopher M Booth Source Type: research
Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda
CONCLUSION: Despite health insurance which covers many elements of cancer care, a substantial proportion of patients on anti-cancer treatment in Rwanda experience major financial toxicity. Novel health financing solutions are needed to ensure accessible and affordable cancer care.PMID:37897406 | DOI:10.1093/oncolo/oyad291 (Source: The Oncologist)
Source: The Oncologist - October 28, 2023 Category: Cancer & Oncology Authors: Fidel Rubagumya Brooke Wilson Achille Manirakiza Emmanuel Mutabazi Diane A Ndoli Emmanuel Rudakemwa Mary D Chamberlin Wilma M Hopman Christopher M Booth Source Type: research
Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda
CONCLUSION: Despite health insurance which covers many elements of cancer care, a substantial proportion of patients on anti-cancer treatment in Rwanda experience major financial toxicity. Novel health financing solutions are needed to ensure accessible and affordable cancer care.PMID:37897406 | DOI:10.1093/oncolo/oyad291 (Source: The Oncologist)
Source: The Oncologist - October 28, 2023 Category: Cancer & Oncology Authors: Fidel Rubagumya Brooke Wilson Achille Manirakiza Emmanuel Mutabazi Diane A Ndoli Emmanuel Rudakemwa Mary D Chamberlin Wilma M Hopman Christopher M Booth Source Type: research
